Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner

被引:36
|
作者
Viswanath, Pavithra [1 ]
Radoul, Marina [1 ]
Izquierdo-Garcia, Jose Luis [2 ,3 ]
Luchman, Hema Artee [4 ,5 ]
Cairncross, J. Gregory [6 ,7 ]
Pieper, Russell O. [8 ]
Phillips, Joanna J. [8 ]
Ronen, Sabrina M. [1 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 1700 4th St,Box 2532,Byers Hall,3rd Floor,Suite, San Francisco, CA 94143 USA
[2] CNIC, Madrid, Spain
[3] CIBER Enfermedades Resp CIBERES, Madrid, Spain
[4] Univ Calgary, Dept Cell Biol & Anat, Calgary, AB, Canada
[5] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada
[6] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[7] Univ Calgary, Southern Alberta Canc Res Inst, Calgary, AB, Canada
[8] Univ Calif San Francisco, Helen Diller Res Ctr, Dept Neurol Surg, San Francisco, CA 94143 USA
关键词
IDH1; mutation; 2-Hydroxyglutarate; Metabolic reprogramming; Magnetic resonance spectroscopy; Phosphocholine; Phosphoethanolamine; Choline kinase; Ethanolamine kinase; HIF-1; alpha; Brain tumors; MAGNETIC-RESONANCE-SPECTROSCOPY; CHOLINE KINASE ALPHA; CANCER-CELLS; PHOSPHOLIPID-METABOLISM; R132H MUTATION; P-31; NMR; HYPOXIA; BIOSYNTHESIS; PHOSPHATIDYLCHOLINE; DIFFERENTIATION;
D O I
10.1186/s40170-018-0178-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Magnetic resonance spectroscopy (MRS) studies have identified elevated levels of the phospholipid precursor phosphocholine (PC) and phosphoethanolamine (PE) as metabolic hallmarks of cancer. Unusually, however, PC and PE levels are reduced in mutant isocitrate dehydrogenase 1 (IDHmut) gliomas that produce the oncometabolite 2-hydroxyglutarate (2-HG) relative to wild-type IDH1 (IDHwt) gliomas. The goal of this study was to determine the molecular mechanism underlying this unusual metabolic reprogramming in IDHmut gliomas. Methods: Steady-state PC and PE were quantified using P-31-MRS. To quantify de novo PC and PE synthesis, we used C-13-MRS and measured flux to C-13-PC and C-13-PE in cells incubated with [1,2-C-13]-choline and [1,2-C-13]-ethanolamine. The activities of choline kinase (CK) and ethanolamine kinase (EK), the enzymes responsible for PC and PE synthesis, were quantified using P-31-MR-based assays. To interrogate the role of 2-HG, we examined IDHwt cells incubated with 2-HG and, conversely, IDHmut cells treated with the IDHmut inhibitor AGI-5198. To examine the role of hypoxia-inducible factor 1-alpha (HIF-1 alpha), we silenced HIF-1 alpha using RNA interference. To confirm our findings in vivo and in the clinic, we studied IDHwt and IDHmut orthotopic tumor xenografts and glioma patient biopsies. Results: De novo synthesis of PC and PE was reduced in IDHmut cells relative to IDHwt. Concomitantly, CK activity and EK activity were reduced in IDHmut cells. Pharmacological manipulation of 2-HG levels established that 2-HG was responsible for reduced CK activity, EK activity, PC and PE. 2-HG has previously been reported to stabilize levels of HIF-1 alpha, a known regulator of CK activity. Silencing HIF-1 alpha in IDHmut cells restored CK activity, EK activity, PC and PE to IDHwt levels. Our findings were recapitulated in IDHmut orthotopic tumor xenografts and, most importantly, in IDHmut patient biopsies, validating our findings in vivo and in the clinic. Conclusions: This study identifies, to our knowledge for the first time, a direct role for 2-HG in the downregulation of CK and EK activity, and thereby, PC and PE synthesis in IDHmut gliomas. These results highlight the unusual reprogramming of phospholipid metabolism in IDHmut gliomas and have implications for the identification of MRS-detectable metabolic biomarkers associated with 2-HG status.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
    Hujber, Zoltan
    Petovari, Gabor
    Szoboszlai, Norbert
    Danko, Titanilla
    Nagy, Noemi
    Kriston, Csilla
    Krencz, Ildiko
    Paku, Sandor
    Ozohanics, Oliver
    Drahos, Laszlo
    Jeney, Andras
    Sebestyen, Anna
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36
  • [22] Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas
    Arita, Hideyuki
    Narita, Yoshitaka
    Matsushita, Yuko
    Fukushima, Shintaro
    Yoshida, Akihiko
    Takami, Hirokazu
    Miyakita, Yasuji
    Ohno, Makoto
    Shibui, Soichiro
    Ichimura, Koichi
    BRAIN TUMOR PATHOLOGY, 2015, 32 (01) : 22 - 30
  • [23] Hyperpolarized 13C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring
    Chaumeil, Myriam M.
    Radoul, Marina
    Najac, Chloe
    Eriksson, Pia
    Viswanath, Pavithra
    Blough, Michael D.
    Chesnelong, Charles
    Luchman, H. Artee
    Cairncross, J. Gregory
    Ronen, Sabrina M.
    NEUROIMAGE-CLINICAL, 2016, 12 : 180 - 189
  • [24] Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas
    Tuna, Gamze
    Dal-Bekar, Nazli Ecem
    Akay, Ali
    Ruksen, Mete
    Islekel, Sertac
    Islekel, Gul Huray
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2022, 81 (07) : 502 - 510
  • [25] Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1
    Ma, Ding
    Zhan, Daqian
    Fu, Yi
    Wei, Shuang
    Lal, Bachchu
    Wang, Jie
    Li, Yunqing
    Lopez-Bertoni, Hernando
    Yalcin, Fatih
    Dzaye, Omar
    Eberhart, Charles G.
    Laterra, John
    Wilson, Mary Ann
    Ying, Mingyao
    Xia, Shuli
    CANCER LETTERS, 2021, 517 : 35 - 45
  • [26] Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas
    Kato, Yukinari
    BRAIN TUMOR PATHOLOGY, 2015, 32 (01) : 3 - 11
  • [27] D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells
    Zhang, Lingjun
    Sorensen, Mia D.
    Kristensen, Bjarne W.
    Reifenberger, Guido
    McIntyre, Thomas M.
    Lin, Feng
    CLINICAL CANCER RESEARCH, 2018, 24 (21) : 5381 - 5391
  • [28] IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
    Molenaar, Remco J.
    Radivoyevitch, Tomas
    Nagata, Yasunobu
    Khurshed, Mohammed
    Przychodzen, Bartolomiej
    Makishima, Hideki
    Xu, Mingjiang
    Bleeker, Fonnet E.
    Wilmink, Johanna W.
    Carraway, Hetty E.
    Mukherjee, Sudipto
    Sekeres, Mikkael A.
    van Noorden, Cornelis J. F.
    Maciejewski, Jaroslaw P.
    CLINICAL CANCER RESEARCH, 2018, 24 (07) : 1705 - 1715
  • [29] Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
    Andronesi, Ovidiu C.
    Rapalino, Otto
    Gerstner, Elizabeth
    Chi, Andrew
    Batchelor, Tracy T.
    Cahil, Dan P.
    Sorensen, A. Gregory
    Rosen, Bruce R.
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (09) : 3659 - 3663
  • [30] Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas: A Preliminary Report and Literature Review
    Johnson, Gabrielle W.
    Han, Rowland H.
    Smyth, Matthew D.
    Leuthardt, Eric C.
    Kim, Albert H.
    CURRENT ONCOLOGY, 2022, 29 (04) : 2550 - 2563